Clinical trial

Letrozole Versus Hormonal Preparation in Frozen Cycles of PCOS Patients. Randomized Controlled Study

Name
DSREC-09/2020_16
Description
One of the indications of freezing is to reduce the risk of ovarian hyperstimulation syndrome particularly in polycystic ovarian disease (PCOS) women. Very few RCTs addressed the issue of optimizing the endometrium for a frozen cycle. Interestingly, Letrozole for ovarian stimulation showed significantly better reproductive outcome when compared with hormone replacement therapy (HRT) cycle. In addition, HRT cycle has been associated with higher miscarriage rate when compared with natural cycle frozen embryo transfer. Nevertheless, there is not yet a well-designed prospective randomized study comparing letrozole and HRT in PCOS women undergoing frozen embryo transfer.
Trial arms
Trial start
2023-08-01
Estimated PCD
2024-02-01
Trial end
2024-04-01
Status
Withdrawn
Phase
Early phase I
Treatment
Letrozole 2.5mg
Letrozole 5 mg starting on day 3 of spontaneous menstrual period or after progesterone withdrawal bleeding for five consecutive days.
Arms:
PCOS women will receive Estradiol and Progesterone (hormonal endometrial preparation)., PCOS women will receive letrozole ovarian stimulation.
Other names:
estradiol and progesterone
Primary endpoint
livebirth rate per embryo transfer
9 months
Eligibility criteria
Inclusion Criteria: * Women with PCOS diagnosed with Rotterdam criteria. * Age between 20 to 40-year-old * Undergoing frozen oocytes intracytoplasmic sperm injection transfer or frozen embryo transfer * Willingly accept to participate in the study Exclusion Criteria: * Women \> 40 years old or younger than 20. * Uterine pathology that decreases the chance of pregnancy or increases risk of miscarriage such as * Uterine fibroids (sub-mucous of any size or intramural of \> 3 cm) * Uncontrolled endocrinal-pathological disease like * Cushing syndrome, * Adrenal hyperplasia, * Hyperprolactinemia, * Acromegaly, * Thyroid disease, * Diabetes mellitus, and * Immune disorders. * Presence of Hydrosalpinx * Not willing or able to sign the consent form.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}
Updated at
2024-02-20

1 organization

1 product

6 indications

Product
Letrozole
Indication
Letrozole
Indication
Live Birth
Indication
Miscarriage